製品番号: HY-13910

テノホビル

(別名: Tenofovir; GS 1278; PMPA)

10 Cited Publications

カスタマーレビュー

Based on 10 publication(s) in Google Scholar

Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.92%
CAS 番号: 147127-20-6
分子式: C₉H₁₄N₅O₄P
分子量:287.21

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tenofovir 構造式

CAS 番号: 147127-20-6

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (10)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)^[1].

IC₅₀ & Target

HIV-1

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Bone marrow cell	CC₅₀	3.5 μM Compound: 2, TFV	Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay	[PMID: 20439609]
Bone marrow cell	CC₅₀	4.7 μM Compound: 2, TFV	Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay	[PMID: 20439609]
C3H/3T3	EC₅₀	0.23 μM Compound: (R)-PMPA, Tenofovir	Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days	[PMID: 18556209]
C8166	EC₅₀	7.1 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	CC₅₀	>250 μM Compound: 1	In vitro cytotoxic concentration against CEM cells In vitro cytotoxic concentration against CEM cells	[PMID: 11327587]
CCRF-CEM	EC₅₀	3.67 μM Compound: 1	In vitro antiviral activity against HIV-1 in CEM cells In vitro antiviral activity against HIV-1 in CEM cells	[PMID: 11327587]
CCRF-CEM	EC₅₀	3.67 μM Compound: 1	In vitro antiviral activity against HIV-2 in CEM cells In vitro antiviral activity against HIV-2 in CEM cells	[PMID: 11327587]
CCRF-CEM	EC₅₀	3 μM Compound: Tenofovir	Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line	[PMID: 12801219]
CCRF-CEM	EC₅₀	4.2 μM Compound: Tenofovir	Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line	[PMID: 12801219]
CCRF-CEM	IC₅₀	>350 μM Compound: Tenofovir	Antiproliferative activity was determined against human T-lymphocyte cells-CEM Antiproliferative activity was determined against human T-lymphocyte cells-CEM	[PMID: 12801219]
CCRF-CEM	CC₅₀	0.41 mM Compound: (R)PMPA	Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro. Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro.	[PMID: 14584956]
CCRF-CEM	CC₅₀	0.41 μM/mL Compound: (R)PMPA	Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro. Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro.	[PMID: 14584956]
CCRF-CEM	EC₅₀	0.0012 mM Compound: (R)PMPA	Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells. Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells.	[PMID: 14584956]
CCRF-CEM	EC₅₀	0.0012 μM/mL Compound: (R)PMPA	Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells. Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells.	[PMID: 14584956]
CCRF-CEM	EC₅₀	0.0014 mM Compound: (R)PMPA	Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells. Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells.	[PMID: 14584956]
CCRF-CEM	EC₅₀	0.0014 μM/mL Compound: (R)PMPA	Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells. Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells.	[PMID: 14584956]
CCRF-CEM	CC₅₀	>250 μM Compound: (R)-PMPA	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	3.2 μM Compound: (R)-PMPA	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	4.6 μM Compound: (R)-PMPA	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	CC₅₀	>250 μM Compound: (R)-PMPA, Tenofovir	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 21803462]
CCRF-CEM	EC₅₀	4.1 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	CC₅₀	>500 μM Compound: 2, (R)-PMPA	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24686012]
CCRF-CEM	EC₅₀	3.7 μM Compound: 2, (R)-PMPA	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	3.9 μM Compound: 2, (R)-PMPA	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	IC₅₀	6.9 μM Compound: 2, (R)-PMPA	Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
CCRF-CEM	CC₅₀	>100 μM Compound: Tenofovir	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation	[PMID: 25617695]
CCRF-CEM	EC₅₀	3.7 μM Compound: Tenofovir	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	EC₅₀	3.9 μM Compound: Tenofovir	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	CC₅₀	>100 μM Compound: Tenofovir	Cytotoxicity against human CEM cells assessed as cell count after 3 days Cytotoxicity against human CEM cells assessed as cell count after 3 days	[PMID: 26513643]
CCRF-CEM	EC₅₀	3.7 μM Compound: Tenofovir	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	EC₅₀	3.9 μM Compound: Tenofovir	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	CC₅₀	>100 μM Compound: 1; (R)-PMPA	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation	[PMID: 38086193]
CHO	CC₅₀	173 μM Compound: Tenofovir	Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	21 μM Compound: Tenofovir	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	435 μM Compound: Tenofovir	Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
E6SM	EC₅₀	>0.17 mM Compound: (R)PMPA	Antiviral activity against G strain of HSV-2 in E6SM cells. Antiviral activity against G strain of HSV-2 in E6SM cells.	[PMID: 14584956]
E6SM	EC₅₀	>0.17 mM Compound: (R)PMPA	Antiviral activity against KOS strain of HSV-1 in E6SM cells. Antiviral activity against KOS strain of HSV-1 in E6SM cells.	[PMID: 14584956]
FM3A	IC₅₀	>350 μM Compound: Tenofovir	Antiproliferative activity was determined against murine mammary carcinoma cells (FM3A) Antiproliferative activity was determined against murine mammary carcinoma cells (FM3A)	[PMID: 12801219]
H9	CC₅₀	>100 μM Compound: (R)-PMPA, Tenofovir	Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay	[PMID: 21803462]
H9	EC₅₀	0.04 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.1 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.15 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.23 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
H9	EC₅₀	0.24 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade B isolate 2101 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade B isolate 2101 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.34 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade C isolate 2914 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade C isolate 2914 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.51 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.69 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade B isolate 1722 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade B isolate 1722 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	0.83 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade C isolate 4110 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade C isolate 4110 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	1.25 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade B isolate 2056 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade B isolate 2056 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	5.61 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against HIV1 clade A isolate 4113 infected in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 clade A isolate 4113 infected in human H9 cells assessed as inhibition of viral replication	[PMID: 21803462]
H9	EC₅₀	8.3 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
HEK-293T	CC₅₀	>100 μM Compound: PMPA	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	CC₅₀	>100 μM Compound: TFV	Cytotoxicity against HEK293T cells assessed as reduction in cell viability in absence of HSA measured after 48 hrs by CellTiter 96 Aqueous One Solution reagent based cell proliferation assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability in absence of HSA measured after 48 hrs by CellTiter 96 Aqueous One Solution reagent based cell proliferation assay	[PMID: 34459598]
HEK-293T	CC₅₀	35.4 μM Compound: TFV	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CellTiter 96 Aqueous One Solution reagent based cell proliferation assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CellTiter 96 Aqueous One Solution reagent based cell proliferation assay	[PMID: 34459598]
HEL	EC₅₀	>0.17 mM Compound: (R)PMPA	Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells. Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.	[PMID: 14584956]
HEL	EC₅₀	>0.17 mM Compound: (R)PMPA	Antiviral activity against Davis strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells. Antiviral activity against Davis strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.	[PMID: 14584956]
HEL	EC₅₀	>0.17 mM Compound: (R)PMPA	Antiviral activity against vaccinia virus in HEL (human erythroleukemia) cells. Antiviral activity against vaccinia virus in HEL (human erythroleukemia) cells.	[PMID: 14584956]
HEL	EC₅₀	0.17 mM Compound: (R)PMPA	Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells. Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.	[PMID: 14584956]
HEL	EC₅₀	0.17 mM Compound: (R)PMPA	Antiviral activity against OKA strain of VZV in HEL (human erythroleukemia) cells. Antiviral activity against OKA strain of VZV in HEL (human erythroleukemia) cells.	[PMID: 14584956]
HEL	EC₅₀	>200 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21803462]
HEL	EC₅₀	>200 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against Herpes simplex virus type 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21803462]
HEL	EC₅₀	>200 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against TK-deficient and ACR-resistant Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against TK-deficient and ACR-resistant Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21803462]
HEL	EC₅₀	>200 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21803462]
HEL	EC₅₀	>100 μM Compound: 2, (R)-PMPA	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24686012]
HEL	EC₅₀	105 μM Compound: 2, (R)-PMPA	Antiviral activity against Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24686012]
HEL	EC₅₀	122 μM Compound: 2, (R)-PMPA	Antiviral activity against Herpes simplex virus G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24686012]
HEL	EC₅₀	151 μM Compound: 2, (R)-PMPA	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24686012]
HeLa	IC₅₀	17 μM Compound: 2, (R)-PMPA	Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
HepG2	CC₅₀	>100 μM Compound: PMPA, tenofovir	Cytotoxicity against human HepG2 cells by MTS assay Cytotoxicity against human HepG2 cells by MTS assay	[PMID: 17646420]
HepG2	IC₅₀	12.3 μM Compound: PMPA, 2	Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay	[PMID: 17888662]
HepG2	CC₅₀	15.04 μM Compound: TDF	Cytotoxicity in human HepG2 cells assessed as induction of cell killing Cytotoxicity in human HepG2 cells assessed as induction of cell killing	[PMID: 32421339]
HepG2 2.2.15	CC₅₀	>300 μM Compound: PMPA, tenofovir	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red uptake assay	[PMID: 17646420]
HepG2 2.2.15	EC₅₀	7.2 μM Compound: PMPA, tenofovir	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as viral DNA levels treated for 9 days measured after 24 hrs Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as viral DNA levels treated for 9 days measured after 24 hrs	[PMID: 17646420]
HepG2 2.2.15	CC₅₀	>1740 μM Compound: Tenofovir	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 21292495]
HepG2 2.2.15	CC₅₀	>1820.42 μM Compound: TF	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	[PMID: 22472044]
HepG2 2.2.15	IC₅₀	0.77 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by RT-PCR analysis	[PMID: 22472044]
HepG2 2.2.15	IC₅₀	1236.61 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HbeAg secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HbeAg secretion by ELISA	[PMID: 22472044]
HepG2 2.2.15	IC₅₀	1446.35 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HBsAg secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HBsAg secretion by ELISA	[PMID: 22472044]
HepG2 2.2.15	CC₅₀	>1756.36 μM Compound: TF	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	0.89 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	1248.76 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release	[PMID: 22520261]
HepG2 2.2.15	IC₅₀	1442.23 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release	[PMID: 22520261]
HepG2 2.2.15	CC₅₀	>1740.95 μM Compound: TF	Cytotoxicity against human HepG2(2.2.15) cells by modified-MTT assay Cytotoxicity against human HepG2(2.2.15) cells by modified-MTT assay	[PMID: 22687441]
HepG2 2.2.15	IC₅₀	0.68 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by PCR analysis	[PMID: 22687441]
HepG2 2.2.15	IC₅₀	1160.23 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion by ELISA	[PMID: 22687441]
HepG2 2.2.15	IC₅₀	1450.11 μM Compound: TF	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion by ELISA	[PMID: 22687441]
HepG2 2.2.15	CC₅₀	>1740 μM Compound: Tenofovir	Cytotoxicity against human HepG2.2.15 cells Cytotoxicity against human HepG2.2.15 cells	[PMID: 23385212]
HepG2 2.2.15	IC₅₀	0.49 μM Compound: Tenofovir	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication	[PMID: 23385212]
HepG2 2.2.15	IC₅₀	1160.2 μM Compound: Tenofovir	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral e antigen production Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral e antigen production	[PMID: 23385212]
HepG2 2.2.15	IC₅₀	1572.1 μM Compound: Tenofovir	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral surface antigen production Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral surface antigen production	[PMID: 23385212]
HepG2 2.2.15	CC₅₀	>1716 μM Compound: Tf	Cytotoxicity against human HepG2.2.15 cells by MTT assay Cytotoxicity against human HepG2.2.15 cells by MTT assay	[PMID: 24731274]
HepG2 2.2.15	IC₅₀	0.71 μM Compound: Tf	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication	[PMID: 24731274]
HepG2 2.2.15	IC₅₀	1238 μM Compound: Tf	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B e antigen secretion by ELISA Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B e antigen secretion by ELISA	[PMID: 24731274]
HepG2 2.2.15	IC₅₀	1389 μM Compound: Tf	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B surface antigen secretion by ELISA Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B surface antigen secretion by ELISA	[PMID: 24731274]
HepG2 2.2.15	CC₅₀	>1742.2 μM Compound: Tenofovir	Cytotoxicity against human HepG 2.2.15 cells by MTT assay Cytotoxicity against human HepG 2.2.15 cells by MTT assay	[PMID: 25737008]
HepG2 2.2.15	IC₅₀	>1742.2 μM Compound: Tenofovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBeAg secretion after 72 hrs by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBeAg secretion after 72 hrs by ELISA	[PMID: 25737008]
HepG2 2.2.15	IC₅₀	>1742.2 μM Compound: Tenofovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 72 hrs by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 72 hrs by ELISA	[PMID: 25737008]
HepG2 2.2.15	IC₅₀	2.9 μM Compound: Tenofovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as decrease in viral DNA replication treated for 7 days by real time PCR analysis Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as decrease in viral DNA replication treated for 7 days by real time PCR analysis	[PMID: 25737008]
HepG2 2.2.15	CC₅₀	1.85 mM Compound: TF	Cytotoxicity against human HepG2(2.2.15) cells after 72 hrs by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 72 hrs by MTT assay	[PMID: 25737009]
HepG2 2.2.15	CC₅₀	399 μM Compound: Tenofovir	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 28082068]
HepG2 2.2.15	CC₅₀	435.22 μM Compound: TFV	Cytotoxicity against human HepG2.2.15 cells infected with HBV Cytotoxicity against human HepG2.2.15 cells infected with HBV	[PMID: 31223460]
HepG2 2.2.15	EC₅₀	6.4 x 10^-5 μM Compound: TDF	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	[PMID: 32421339]
Huh-7	EC₅₀	16 μM Compound: tenofovir, TDF	Inhibition of wild type HBV replication in Huh7 cells Inhibition of wild type HBV replication in Huh7 cells	[PMID: 17371827]
Huh-7	CC₅₀	>1000 μM Compound: tenofovir, TDF	Effect on cell viability in human Huh7 cells Effect on cell viability in human Huh7 cells	[PMID: 17371827]
Huh-7	CC₅₀	>150 μM Compound: (R)-PMPA, Tenofovir	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 21803462]
Huh-7	EC₅₀	4.2 μM Compound: (R)-PMPA, Tenofovir	Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis	[PMID: 21803462]
L1210	IC₅₀	>350 μM Compound: Tenofovir	Antiproliferative activity was determined against murine leukemia cells (L1210) Antiproliferative activity was determined against murine leukemia cells (L1210)	[PMID: 12801219]
L1210	IC₅₀	11 μM Compound: 2, (R)-PMPA	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 24686012]
MOLT-4	IC₅₀	>350 μM Compound: Tenofovir	Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8 Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8	[PMID: 12801219]
MT2	CC₅₀	>200 μM Compound: 2	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 17562366]
MT2	EC₅₀	3.6 μM Compound: 2	Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days	[PMID: 17562366]
MT2	CC₅₀	>100 μM Compound: PMPA, tenofovir	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 17646420]
MT2	EC₅₀	0.65 μM Compound: PMPA, tenofovir	Antiviral activity against HIV1 LAI in human MT2 cells assessed as inhibition of p24 antigen production by ELISA Antiviral activity against HIV1 LAI in human MT2 cells assessed as inhibition of p24 antigen production by ELISA	[PMID: 17646420]
MT2	CC₅₀	>1000 μM Compound: 1, Tenofovir, PMPA	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 18029175]
MT2	EC₅₀	3.6 μM Compound: tenofovir	Antiviral activity against HIV1 3B in MT2 cells Antiviral activity against HIV1 3B in MT2 cells	[PMID: 18082402]
MT2	CC₅₀	>1000 μM Compound: tenofovir	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 18082402]
MT2	CC₅₀	>500 μM Compound: 1, PMPA, tenofovir	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 18164198]
MT2	EC₅₀	3.6 μM Compound: 1, PMPA, tenofovir	Antiviral activity against wild type HIV1 3B in MT2 cells Antiviral activity against wild type HIV1 3B in MT2 cells	[PMID: 18164198]
MT2	IC₅₀	0.38 μM Compound: 1, PMPA, tenofovir	Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells	[PMID: 18164198]
MT2	EC₅₀	3.6 μM Compound: 1, PMPA	Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay	[PMID: 19179082]
MT2	CC₅₀	>1000 μM Compound: 1, PMPA	Cytotoxicity against human MT2 cells after 5 days Cytotoxicity against human MT2 cells after 5 days	[PMID: 19179082]
MT2	EC₅₀	13 nM Compound: 2, PMPA or TFV	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by XTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by XTT assay	[PMID: 20409721]
MT2	CC₅₀	>50000 nM Compound: 2, PMPA or TFV	Cytotoxicity against human MT2 cells after 5 days by XTT assay Cytotoxicity against human MT2 cells after 5 days by XTT assay	[PMID: 20409721]
MT2	EC₅₀	5 μM Compound: Tenofovir	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 5 days by XTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 5 days by XTT assay	[PMID: 27748590]
MT2	CC₅₀	>100 μM Compound: TFV	Cytotoxicity against human MT2 cells assessed as cell viability by CellTiter Glo assay Cytotoxicity against human MT2 cells assessed as cell viability by CellTiter Glo assay	[PMID: 34549952]
MT4	CC₅₀	197 μM Compound: 1	In vitro cytotoxic concentration against MT-4 cells In vitro cytotoxic concentration against MT-4 cells	[PMID: 11327587]
MT4	EC₅₀	1.4 μM Compound: 1	In vitro antiviral activity against HIV-2 in MT-4 cells In vitro antiviral activity against HIV-2 in MT-4 cells	[PMID: 11327587]
MT4	EC₅₀	2.3 μM Compound: 1	In vitro antiviral activity against HIV-1 in MT-4 cells In vitro antiviral activity against HIV-1 in MT-4 cells	[PMID: 11327587]
MT4	EC₅₀	0 μM Compound: TDF	Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay	[PMID: 17548498]
MT4	CC₅₀	>20 μM Compound: PMPA	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay	[PMID: 28682067]
PBMC	CC₅₀	53 μM Compound: TDF	Cytotoxicity against human PHA-PBMC cells by MTT assay Cytotoxicity against human PHA-PBMC cells by MTT assay	[PMID: 17548498]
PBMC	CC₅₀	1270 μM Compound: PMPA, tenofovir	Cytotoxicity against human PBMC by XTT assay Cytotoxicity against human PBMC by XTT assay	[PMID: 17646420]
PBMC	CC₅₀	>100 μM Compound: (R)-PMPA, Tenofovir	Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay	[PMID: 21803462]
PBMC	CC₅₀	>100 μM Compound: TFV	Cytotoxicity against human PBMC assessed as reduction in cell viability by XTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability by XTT assay	[PMID: 27405794]
PBMC	CC₅₀	>100 μM Compound: TFV	Cytotoxicity in uninfected human PBMC assessed as reduction in cell viability by XTT assay Cytotoxicity in uninfected human PBMC assessed as reduction in cell viability by XTT assay	[PMID: 27933889]
PBMC	CC₅₀	>25 μM Compound: PMPA	Cytotoxicity against human PHA-stimulated PBMC assessed as cell viability by tetrazolium dye assay Cytotoxicity against human PHA-stimulated PBMC assessed as cell viability by tetrazolium dye assay	[PMID: 28682067]
PBMC	CC₅₀	≥10 μM Compound: (R)-PMPA; Tenofovir	Cytotoxicity against human PBMC assessed as reduction in cell growth after 7 days by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell growth after 7 days by MTT assay	[PMID: 29558735]
TZM	CC₅₀	>100 μM Compound: PMPA	Cytotoxicity against human TZM-bl cells assessed as cell viability by tetrazolium dye assay Cytotoxicity against human TZM-bl cells assessed as cell viability by tetrazolium dye assay	[PMID: 28682067]
Vero C1008	CC₅₀	35.4 μM Compound: TFV	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 38925014]

体外実験

Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC₅₀ values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage^[1]. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1_BaL and X4-tropic HIV-1_IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1_BaL, and is not toxic to PBMCs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice^[3]. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 147127-20-6
性状 Solid
分子量 287.21
分子式 C₉H₁₄N₅O₄P
Color White to off-white
SMILES

C[C@@H](OCP(O)(O)=O)CN1C=NC2=C(N)N=CN=C12
別名

Tenofovir; GS 1278; PMPA
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]

2022 Dec;9(34):e2203088. PMID: 36257906
Nanoscale

The memristive effect as a novelty in drug monitoring. [Abstract]

2017 Jul 13;9(27):9676-9684. PMID: 28675222
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Pharm Res

Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease. [Abstract]

2023 Nov;40(11):2597-2606. PMID: 37704895

Tenofovir purchased from MedChemExpress. Usage Cited in: Pharm Res. 2023 Nov;40(11):2597-2606. [Abstract]

Uremic solute inhibition of Tenofovir uptake. Human OAT1 and OAT3-overexpressing and mock-transfected HEK-293 cells were used for inhibition studies. Radiolabeled Tenofovir (0.1 μM) was added with potential inhibitors at specified concentrations for 5 min at 37 °C. Results of Tenofovir uptake were normalized to % of vehicle controls. IC_{50_{shown in insets were calculated based on nonlinear regression curves.}}
Drug Metab Dispos

A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis. [Abstract]

2026 Mar 2;54(5):100263. PMID: 42085925
Antiviral Res

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]

2020 Jun;178:104786. PMID: 32251767
Sci Rep

Aptamer-based Field-Effect Biosensor for Tenofovir Detection. [Abstract]

2017 Mar 15;7:44409. PMID: 28294122
J Chromatogr B Analyt Technol Biomed Life Sci

Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]

2025 Dec 15:1267:124803. PMID: 41072339
bioRxiv

Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. [Abstract]

2025 Aug 14:2025.08.14.670267. PMID: 40832229
Charles University

2019 Jun.

溶剤 & 溶解度

体外:

DMSO : 7.69 mg/mL (26.77 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (6.96 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4818 mL

17.4089 mL

34.8177 mL

5 mM

0.6964 mL

3.4818 mL

6.9635 mL

10 mM

0.3482 mL

1.7409 mL

3.4818 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.77 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.77 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.77 mg/mL (2.68 mM); Clear solution

This protocol yields a clear solution of ≥ 0.77 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1.96 mg/mL (6.82 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

Cells are plated into 48-well tissue culture plates (39,000 cells/mL) and allowed to grow for 48 h followed by treatment with vehicle or Tenofovir. Following the treatment period, cell viability is assessed using the MTT assay. The MTT assay relies on the conversion of tetrazolium dye 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by NAD(P)H-dependent oxidoreductases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Twenty adult chronic WHV carrier woodchucks are stratified equally by age, sex, body weight, and serum GGT activity into five treatment groups consisting of four animals each: (i) Tenofovir Disoproxil Fumarate at 15.0 mg/kg once per day, (ii) Tenofovir Disoproxil Fumarate at 5.0 mg/kg/day, (iii) Tenofovir Disoproxil Fumarate at 1.5 mg/kg/day, (iv) Tenofovir Disoproxil Fumarate at 0.5 mg/kg/day, and (v) a placebo control. The woodchucks are treated daily for 4 weeks and observed for an additional 12 weeks following cessation of drug treatment^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18(3). [Content Brief]

[2]. Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018. [Content Brief]

[3]. Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098. [Content Brief]

[4]. Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.4818 mL	17.4089 mL	34.8177 mL	87.0443 mL
H₂O / DMSO	5 mM	0.6964 mL	3.4818 mL	6.9635 mL	17.4089 mL
DMSO	10 mM	0.3482 mL	1.7409 mL	3.4818 mL	8.7044 mL
	15 mM	0.2321 mL	1.1606 mL	2.3212 mL	5.8030 mL
	20 mM	0.1741 mL	0.8704 mL	1.7409 mL	4.3522 mL
	25 mM	0.1393 mL	0.6964 mL	1.3927 mL	3.4818 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Tenofovir

10 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

テノホビル

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Tenofovir

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (10)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

テノホビル

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Tenofovir

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (10)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Tenofovir 関連分類

製品番号: HY-13910